سعر كوكسوريزيت 90 مجم 30 قرص 2025

Coxorizet 90 mg etoricoxib film-coated tablets, 30 per pack (Zeta Pharma, Egypt).

• Symptomatic relief of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and pain/inflammation of acute gouty arthritis; short-term moderate pain after dental surgery (adults and adolescents ≥16 y).Population: Adults and adolescents 16 years and olderMHRA / eMC

• Very common: abdominal pain. Common: oedema, dizziness, headache, palpitations, hypertension, bronchospasm, constipation, flatulence, gastritis, heartburn, diarrhoea, dyspepsia, nausea, vomiting, ALT/AST increase, ecchymosis, asthenia, flu-like illness, alveolar osteitis.International label, same formulation · MHRA / eMC

• Hypersensitivity to etoricoxib/excipients; active peptic ulcer or GI bleeding; NSAID/aspirin-induced asthma/rhinitis/polyps/angioedema/urticaria; pregnancy and lactation; severe hepatic dysfunction; CrCl <30; age <16; IBD; CHF NYHA II–IV; uncontrolled hypertension (>140/90); established IHD, PAD, and/or cerebrovascular disease.International label, same formulation · MHRA / eMC

• CV thrombotic risk may increase with dose/duration — shortest course, lowest dose. GI PUBs possible. Monitor BP within 2 weeks and periodically. Fluid retention/oedema/hypertension. Hepatic enzyme elevations. Serious skin reactions — stop at first rash. May mask fever. Caution with warfarin. Not a substitute for low-dose aspirin antiplatelet therapy.International label, same formulation · MHRA / eMC

• Warfarin / oral anticoagulantsMajorEtoricoxib 120 mg increased INR ~13%; monitor INR when starting or changing dose.MHRA / eMC
• ACE inhibitors / ARBs / diureticsModerateNSAIDs may reduce antihypertensive effect and worsen renal function in at-risk patients.MHRA / eMC
• MethotrexateModerateAt 120 mg, etoricoxib may increase methotrexate exposure; monitor toxicity.MHRA / eMC

• Contraindicated in pregnancy (prostaglandin synthesis inhibition; uterine inertia; premature ductus closure in late pregnancy). Discontinue if pregnancy occurs.International label, same formulation · MHRA / eMC
• Contraindicated in lactation; unknown if excreted in human milk (excreted in rat milk).International label, same formulation · MHRA / eMC

• Etoricoxib: Selective COX-2 inhibitor within the clinical dose range; no inhibition of COX-1 at doses up to 150 mg daily and no effect on platelet function.